Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06215287
Other study ID # CICL670A2429
Secondary ID EUPAS104950
Status Completed
Phase
First received
Last updated
Start date January 12, 2024
Est. completion date February 15, 2024

Study information

Verified date May 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date February 15, 2024
Est. primary completion date February 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Physicians will be required to meet all of the following inclusion criteria: - Must provide consent for participation - Must spend =50% of time in direct patient care - Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months. - Have prescribed Exjade and/or generic deferasirox within the last 12 months. Exclusion Criteria: Physicians meeting the following criterion will not be eligible to take the survey: • Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physician survey
Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials

Locations

Country Name City State
Switzerland Novartis Investigative Site Basel

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC) The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information:
Administration and dosing of Exjade (deferasirox) FCT
Biological monitoring
Through study completion, an average of 6 months.
See also
  Status Clinical Trial Phase
Completed NCT05440487 - Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
Completed NCT01825512 - Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Phase 3
Completed NCT01740713 - Pharmacokinetic Study of Deferiprone in Paediatric Patients Phase 2
Completed NCT02720536 - Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation Phase 3